Table 2 Means (SD) of secondary outcome variables as a function of study visit and treatment group.
| Treatment Group | Study Visit | |||||||
|---|---|---|---|---|---|---|---|---|
| VE | V2 | V5 | V8 | V9 | V12 | V15 | V18 | |
| CGI-S | ||||||||
| Combination |
1.80 (0.84) |
1.40 (0.55) |
1.60 (0.55) |
1.20 (0.45) |
1.80 (0.45) |
1.60 (0.55) |
1.40 (0.55) |
1.40 (0.55) |
| Monotherapy |
2.46 (0.66) |
1.92 (0.86) |
1.46 (0.66) |
1.54 (0.66) |
1.38 (0.65) |
1.46 (0.52) |
1.54 (0.66) |
1.38 (0.51) |
| Total |
2.28
(0.75) |
1.78
(0.81) |
1.50
(0.62) |
1.44
(0.62) |
1.50
(0.62) |
1.50
(0.51) |
1.50
(0.62) |
1.39
(0.50) |
| CGAS | ||||||||
| Combination |
79.20 (2.39) |
83.00 (2.74) |
81.00 (5.47) |
82.00 (5.70) |
79.00 (2.24) |
80.00 (6.12) |
83.00 (4.47) |
84.00 (2.24) |
| Monotherapy |
73.54 (8.23) |
78.84 (7.68) |
79.23 (7.86) |
80.38 (7.21) |
82.38 (8.30) |
83.46 (3.15) |
82.69 (6.33) |
82.38 (3.84) |
| Total |
75.11
(7.48) |
80.00
(6.85) |
79.72
(7.16) |
80.83
(6.69) |
81.44
(7.22) |
82.50
(4.28) |
82.77
(5.74) |
82.83
(3.48) |
| MADRS | ||||||||
| Combination |
9.40 (6.15) |
4.40 (2.88) |
4.20 (4.08) |
4.80 (4.76) |
6.60 (3.91) |
5.60 (2.88) |
3.00 (3.00) |
2.80 (2.28) |
| Monotherapy |
9.15 (6.01) |
5.54 (6.03) |
3.85 (4.27) |
4.54 (3.62) |
3.15 (3.55) |
3.92 (3.01) |
3.46 (3.30) |
4.15 (3.84) |
| Total |
9.22
(5.86) |
5.22
(5.28) |
3.94
(4.10) |
4.61
(3.82) |
4.11
(3.87) |
4.39
(2.99) |
3.33
(3.14) |
3.78
(3.47) |
| YMRS | ||||||||
| Combination |
0.60 (1.34) |
0.20 (0.45) |
2.20 (3.35) |
1.40 (1.67) |
2.40 (3.78) |
0.40 (0.55) |
0.40 (0.89) |
0.80 (0.84) |
| Monotherapy |
1.92 (3.04) |
1.08 (1.04) |
0.77 (1.69) |
1.31 (2.06) |
0.85 (1.57) |
1.31 (1.84) |
1.00 (2.24) |
1.54 (2.11) |
| Total |
1.56
(2.71) |
0.83
(0.98) |
1.17
(2.25) |
1.33
(1.91) |
1.28
(2.37) |
1.06
(1.62) |
0.83
(1.94) |
1.33
(1.84) |
